menu

QuintilesIMS Blog

Fresh ideas and insights from our experts around the globe

distribution
Brazilians flock to pharmacies: How healthcare companies can bolster sales by embracing this shifting shopper trend
Filtered by 'Orphan Drugs' ×
Barbara Gillespie
Many of the individual diseases that collectively represent ‘kidney disease’ are themselves rare diseases.
Read More
CynthiaJackson
Kathy Beach
How nurse educators help families address treatment obstacles, driving adherence among patients around the world.
Read More
Rob-Stolper
StellaBlackburn
The European Medicine Agency's Adaptive Licensing Pilot project is a uniquely collaborative process designed to allow early and progressive patient access to medicines which address unmet medical needs.
Read More
Susan Tansey
Proving the value of bringing the patient voice into rare disease trial design.
Read More
Key market access learnings from a U.S. launch
The U.S. pharma market is the largest pharma market worldwide , and continues to grow. According to  GlobalData , it was worth around $395.2 billion in 2014, and is estimated to rise to $548.4 billion by 2020. This make it a very attractive one for biopharma, and provides the opportunity to improve patient outcomes for a large population. The benefits offered by the U.S. market include support for the biopharma industry from the government, and access to a well-educated and experienced workforce. Innovation is welcomed in the U.S., particularly where a product or a device offers cost savings through efficacy, safety and improvements in patient outcomes, and this is backed by a well-managed intellectual property system, transparent patent protection processes, and market exclusivity...
Read More
Niti Goel
For a half century, lupus patients – most of them women – had few treatment options and no signs of hope in the world of drug development. But in 2011, when the first new drug approved for systemic lupus erythematosus in more than 50 years entered the market, a new wave of confidence swept across the drug development industry. Today numerous treatments are in development to address this chronic inflammatory disease. Yet, challenges remain for biopharma companies striving to create new drugs for this uncommon disease. A group of experts from Quintiles’ Rheumatology Center of Excellence recently conducted a novel analysis of lupus clinical studies registered in ClinicalTrials.gov between 2004 and 2013 and discovered that there was a three-fold increase in the number of patients...
Read More
Brad Smith
Recent advances in personalized medicine and genomic technologies have led to innovative developments in oncology research and practice. As we develop a better understanding of the biology of cancer we are able to develop drugs to target niche populations of patients with tumors that demonstrate unique molecular alterations. The ability to treat these sub-populations with targeted treatments often results in higher response rates among trial participants which enables the industry to drive these drugs to market faster giving patients access to these important treatments. This is exciting news for researchers, patients, physicians and payers, all of whom benefit from a precision medicine approach for cancer treatment. However, by narrowing the target population down to such specific...
Read More
CynthiaJackson
Although there is no question that pediatric clinical trials are essential to demonstrating the safety and efficacy of treatments for children, conducting these can be frustratingly difficult. They are especially challenging to recruit for, in part because researchers have had little insight into what motivates parents to enroll their children in trials – until now. At the recent American Academy of Pediatrics National Conference , we presented the results of a survey of US parents and caregivers to understand what influences their willingness to enroll their children in clinical trials. The results suggest that our assumptions may need to change: 73% of parents say they are interested in having their child participate in an appropriate clinical trial – yet 96% of them say they have...
Read More